Abcam plc (ABCM) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Cambridge, United Kingdom. Der aktuelle CEO ist Alan Thomas Hirzel BS,.
ABCM hat IPO-Datum 2020-10-22, 1,760 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $5.52B.
Abcam plc is a life science company headquartered in Cambridge, United Kingdom, specializing in the identification, development, and distribution of reagents and tools for scientific research, diagnostics, and drug discovery. The company's product portfolio includes primary and secondary antibodies, conjugated antibodies, immunoassays, proteins and peptides, edited cell lines, and complementary research tools such as cellular activity kits and cell signaling pathway tools. Abcam serves a diverse customer base encompassing academic institutions, research institutes, and commercial entities in the pharmaceutical, biotechnology, and diagnostics sectors. With established operations across the Americas, Europe, Asia Pacific, and other regions, the company distributes its products primarily through online channels. Founded in 1998, Abcam has established itself as a key supplier of essential scientific research materials globally.
